Welcome to our dedicated page for GoodRx Holdings SEC filings (Ticker: GDRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
GoodRx Holdings, Inc. filings document the financial reporting, governance, and public-company controls of a Nasdaq-listed digital healthcare platform for prescription savings. Its 8-K reports furnish quarterly operating results, revenue categories such as prescription transactions, subscriptions, and Pharma Direct, non-GAAP financial measures, and business outlook disclosures tied to medication access and pharmacy-market conditions.
GoodRx regulatory filings also cover proxy governance, board classification matters, director departures, officer appointments and resignations, executive compensation, equity awards under the 2020 Incentive Award Plan, and changes in the company’s independent registered public accounting firm.
GoodRx Holdings, Inc. has changed its independent auditor. The Audit and Risk Committee approved the appointment of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, and dismissed PricewaterhouseCoopers LLP from this role.
PWC’s audit reports on the 2025 and 2024 consolidated financial statements contained no adverse opinions, disclaimers, or qualifications. The company reports no disagreements or reportable events with PwC through March 14, 2026, and states it did not consult KPMG on accounting or auditing matters before this appointment.
GoodRx Holdings, Inc. director Agnes Rey-Giraud exercised stock options to acquire 192,185 shares of Class A common stock at $0.47 per share. On the same date, she made bona fide gifts totaling 150,438 shares, including 75,219 shares transferred to a family trust for which she is the sole trustee and beneficiary. Following these transactions, she continues to hold a substantial direct position in GoodRx stock.
GoodRx Holdings, Inc. Chief Accounting Officer Romin Nabiey reported equity transactions involving restricted stock units and Class A common stock. On March 8, 2026, restricted stock units were converted into a total of 10,201 and 2,233 shares of Class A common stock at a price of $0.00 per share through derivative exercises.
In connection with these conversions, Class A shares were also disposed of under transaction code F to cover tax obligations, with 4,201 shares and 920 shares withheld at a price of $2.28 per share as tax-withholding dispositions. After these transactions, Nabiey directly owned 183,061 shares of Class A common stock.
Footnotes explain that each restricted stock unit represents a contingent right to receive one share of Class A common stock. One award began vesting December 8, 2022 with quarterly installments over 15 quarters, and another will begin vesting June 8, 2024 on a similar quarterly schedule.
GoodRx Holdings, Inc. reported a new executive compensation decision. On March 3, 2026, the Board of Directors, following a recommendation from its Compensation Committee, approved a discretionary cash bonus of $72,918 to Chief Accounting Officer Romin Nabiey for his performance during 2025.
McGinnis Christopher A reported acquisition or exercise transactions in this Form 4 filing.
GoodRx Holdings, Inc. reported that executive Christopher A. McGinnis received a grant of 443,852 restricted stock units on Class A common stock. Each unit represents a right to receive one share at no purchase price.
The restricted stock units vest in 12 equal quarterly installments, with the first vesting on April 15, 2026, and are subject to continued service through each vesting date. Following this award, McGinnis directly holds 126,321 shares of Class A common stock.
GoodRx Holdings, Inc. Chief Accounting Officer Romin Nabiey reported an equity compensation grant. On March 3, 2026, Nabiey acquired 108,189 restricted stock units, each representing a contingent right to receive one share of Class A common stock. These RSUs will vest in 12 equal quarterly installments, with the first vesting date on April 15, 2026, subject to continued service. Following this report, Nabiey held 175,748 shares of Class A common stock directly.
GoodRx Holdings, Inc. reported that director and officer Wendy Lynn Barnes acquired 1,331,557 restricted stock units on March 3, 2026 as an equity award. Each restricted stock unit represents a right to receive one share of Class A common stock.
The award will vest ratably in 12 equal quarterly installments, with the first vesting date on April 15, 2026, subject to her continued service through each vesting date. Following this award, she also held 427,993 shares of Class A common stock directly.
GoodRx Holdings, Inc. reported that board member Dipanjan Deb resigned from its Board of Directors, effective February 26, 2026. The company states that Mr. Deb’s decision to step down was not due to any disagreement with GoodRx or its management regarding operations, policies, or practices.
GoodRx Holdings, Inc. describes its business model as a consumer-focused digital healthcare platform that helps Americans find lower prices on prescription drugs and related services. The company’s core prescription transactions offering still generates most revenue, complemented by subscriptions, telehealth and pharma-direct advertising solutions.
GoodRx highlights a large estimated prescription and pharma-direct market opportunity of $600–$710 billion and positions its data-driven pricing engine, PBM and pharmacy relationships, and brand as key advantages. The filing also outlines significant risks, including PBM and retail pharmacy concentration, store closures, new federal initiatives like TrumpRx.gov, regulation of data privacy and telehealth, shifting cost burdens to consumers, and execution challenges as it expands offerings and manages growth.
GoodRx Holdings, Inc. reported fourth quarter 2025 revenue of $194.8 million and full year 2025 revenue of $796.9 million, up slightly from 2024. Full year net income rose to $30.4 million with a 3.8% net margin, while Adjusted EBITDA reached $270.5 million and a 33.9% margin. Growth was driven by a 41% increase in 2025 Pharma Direct revenue to $151.4 million, partly offset by declines in prescription transactions and subscription revenue. The company generated $167.9 million in operating cash flow, ended 2025 with $261.8 million in cash and $495.0 million of total debt, and repurchased 48.9 million Class A shares for $217.4 million. For 2026, management guides revenue to $750–$780 million and Adjusted EBITDA of more than $230 million, implying a year-over-year decline in both metrics while maintaining strong profitability.